LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 03, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced presentations at the following conferences taking place in April:

World Orphan Drug Congress USA, April 19 - 21 2017, at the Washington Marriott Wardman Park in Washington D.C.

  • Matt Kapusta, Chief Executive Officer, will be presenting a keynote address: Adeno-associated virus (AAV)-based gene therapies for rare, chronic and degenerative diseases, on Friday April 21st, 2017, 9.40 a.m. EDT.

12th Annual HD Therapeutics Conference by CHDI, April 24 - 27 2017, at the Westin Dragonara Resort in St. Julian's, Malta.

  • A presentation new preclinical data on huntingtin gene silencing in a mini-pig model of Huntington's Disease, using allele-specific and non-selective miRNAs, will be presented during the CHDI conference.

Gene Therapy for Rare Disorders Conference, April 25 - 26 2017, at the Sheraton Boston Hotel, in Boston MA.

  • Lance Weed, Vice President of US Operations, will be presenting: Optimizing the Scalability of Gene Therapy Manufacturing, on Tuesday April 25th, 2017, 2.00 p.m. EDT.
  • Eileen Sawyer, Director of Global Medical Affairs, will be presenting: Bridging Gaps Through Early Integration of the Internal Medical Affairs Function, on Wednesday April 26th, 2017, 11.00 a.m. EDT.
  • Daniel Leonard, Director of Global Patient Advocacy, will be presenting: The Intersection of Patient Advocacy and Gene Therapy: A Case Study in Hemophilia, on Wednesday April 26th, 2017, 2.00 p.m. EDT.

Alliance for Regenerative Medicines (ARM)'s 5th Annual Cell & Gene Therapy Investor Day, April 27th 2017, at The State Room, in Boston MA.

  • Matthew Kapusta, chief executive officer, will be participating in a fireside chat on Thursday, April 27th, 2017, 2.15 p.m. EDT.

The Company also announced its participation in the following conferences taking place in April:

Hemophilia Federation of America (HFA)'s Annual Symposium, April 6 - 9 2017, at the Rhode Island Convention Center in Providence, RI.

The International Liver Congress 2017 by EASL, April 19 - 23 2017 at the RAI in Amsterdam, The Netherlands.

About uniQure 
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington's disease and cardiovascular diseases. www.uniQure.com

uniQure Contacts:

Maria E. Cantor
Direct: 339-970-7536
Mobile:  617-680-9452
m.cantor@uniQure.com 

Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79 
e.mulder@uniQure.com 

Tom Malone
Direct:  339-970-7558
Mobile:  339-223-8541
t.malone@uniQure.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: uniQure N.V. via Globenewswire
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more uniQure NV Charts.
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more uniQure NV Charts.